| The impact of extirpation of non-palpable/normal-sized regional lymph nodes on staging of canine cutaneous mast cell tumours: A multicentric retrospective study |
12 |
| Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours |
10 |
| Sentinel lymph node mapping by near-infrared fluorescence imaging and contrast-enhanced ultrasound in healthy dogs |
9 |
| Linac-based stereotactic radiation therapy for canine non-lymphomatous nasal tumours: 29 cases (2013-2016) |
8 |
| Diagnostic accuracy of contrast-enhanced computed tomography for assessment of mandibular and medial retropharyngeal lymph node metastasis in dogs with oral and nasal cancer |
8 |
| Intratumoral injection of radioactive holmium ( Ho-166) microspheres for treatment of oral squamous cell carcinoma in cats |
8 |
| Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour |
8 |
| Faecal microbiota in dogs with multicentric lymphoma |
7 |
| LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma |
7 |
| Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma |
7 |
| Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma |
7 |
| Intra-operative imaging of surgical margins of canine soft tissue sarcoma using optical coherence tomography |
6 |
| Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma |
6 |
| Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs |
6 |
| Association of tumour-infiltrating regulatory T cells with adverse outcomes in dogs with malignant tumours |
6 |
| Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide |
6 |
| Metastasis-associated microRNA expression in canine uveal melanoma |
6 |
| The role of sentinel lymph node mapping in small animal veterinary medicine: A comparison with current approaches in human medicine |
5 |
| Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours |
5 |
| Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018 |
5 |
| Influence of surgical margin completeness on risk of local tumour recurrence in canine cutaneous and subcutaneous soft tissue sarcoma: A systematic review and meta-analysis |
5 |
| Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma |
5 |
| Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000-2015) |
5 |
| Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017) |
5 |
| Outcome and prognostic factors in medically treated canine prostatic carcinomas: A multi-institutional study |
5 |
| Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma |
5 |
| Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals |
4 |
| A prospective pilot study on early toxicity from a simultaneously integrated boost technique for canine sinonasal tumours using image-guided intensity-modulated radiation therapy |
4 |
| Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study |
4 |
| Preliminary investigation of extracellular vesicles in mammary cancer of dogs and cats: Identification and characterization |
4 |
| Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses |
4 |
| Clinical features and outcome of dermal squamous cell carcinoma in 193 dogs (1987-2017) |
4 |
| In vitro effects of the activity of novel platinum (II) complex in canine and human cell lines |
4 |
| Soft tissue sarcoma in dogs: A treatment review and a novel approach using electrochemotherapy in a case series |
4 |
| Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines |
4 |
| Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs |
4 |
| Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi-institutional retrospective study of 64 cases |
4 |
| Canine spinal meningiomas and nerve sheath tumours in 34 dogs (2008-2016): Distribution and long-term outcome based upon histopathology and treatment modality |
4 |
| Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: A prospective study |
4 |
| Prognostic significance of hypermethylation of death-associated protein kinase (DAPK) gene CpG island in dogs with high-grade B-cell lymphoma |
4 |
| Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas |
4 |
| Comparison of histologic margin status in low-grade cutaneous and subcutaneous canine mast cell tumours examined by radial and tangential sections |
4 |
| Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells |
4 |
| Outcome following treatment of feline gastrointestinal mast cell tumours |
4 |
| Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology |
4 |
| Aberrant expression of microRNAs and the miR-1/MET pathway in canine hepatocellular carcinoma |
4 |
| Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target |
4 |
| Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom |
4 |
| Novel hyperthermia applicator system allows adaptive treatment planning: Preliminary clinical results in tumour-bearing animals |
3 |
| Anticancer effects of resveratrol in canine hemangiosarcoma cell lines |
3 |
